上海民为生物技术有限公司
SHANGHAI MINWEI BIOTECHNOLOGY CO.,LTD

Go

T2 DM

Obesity
Hyperlipidemia
Others
LAGMA™ directed screening system

Pipelines

Product Development Process

Drug Development


Research Areas

Technology Platforms

MWX205 injection is currently the world's first siRNA drug targeting both PCSK9 and ANGPTL3 that has entered the clinical trial stage. This marks that Shanghai Minwei Biotechnology has entered a new stage of dual-target siRNA innovation research and development in the field of metabolic and cardiovascular disease treatment
2026-06
News Center
ABOUT US

Shanghai Minwei Biotechnology Co., Ltd. was founded in 2021 and is located in Zhoupu Town, Zhangjiang Science City, Pudong New Area, Shanghai, an area known for its concentration of innovative biopharmaceutical and medical device research and development companies. The company specializes in the innovation and platform development of cutting-edge "multi-core large molecule biopharmaceuticals," aiming to create globally competitive novel drugs.

At present, Minwei has a number of research and development pipelines, and nearly 20 clinical approvals at home and abroad. One of the projects has completed phase II multi-center clinical trials for two indications, and several projects have carried out phase I clinical trials at the same time.

     
hr@minweibiotech.com
021-20961910
Building No.13, Zhangjiang Gene Island, Lane 889, Ziping Road, Zhoupu Town, Pudong new district, Shanghai City
|
|
|
|